Study showed that very low birth weight infants exposed to gastric acid inhibitors have significantly increased odds of developing infections, and that the risk increases with each day of exposure.
Clofazimine was safe and well-tolerated as part of a multidrug regimen for the treatment of children with Mycobacterium abscessus odontogenic infections.
Expert from the National Center for Immunization and Respiratory Diseases, a division of the CDC, discusses prevention strategies for group B streptococcus in infants, including the development of a maternal vaccine.
MenB-FHbp was safe and immunogenic after dose 2 and dose 3 and was also associated with more injection-site reactions than hepatitis A virus vaccine and saline.
Young infants assessed for central nervous system infection rarely have herpes simplex virus.
Infants born via vaginal delivery to mothers exposed to intrapartum antibiotic prophylaxis for group B Streptococcus demonstrated altered fecal microbiota immediately following birth.
Majority of children presented with only 2 of 4 main symptoms (fever, maculopapular rash, conjunctivitis, and/or arthralgia).
Experts discuss the various imaging modalities for children who require diagnostic workup beyond urine culture, as well as the consequences of overusing antibiotics and antibiotic route of administration.
Chest X-rays do not differentiate between viral and bacterial pathogens, and they do not subsequently alter the course of treatment.
Vaccination may confer modest reductions in acute otitis media (AOM) and AOM-targeted antibiotic use but use of influenza vaccine as a strategy to reduce AOM is likely unjustified.
Pleural fluid lactic dehydrogenase and glucose are useful parameters in determining the severity of pediatric CAP.
The results of this study question the routine empirical use of macrolide combination therapy in this population.
Prospective studies are needed to determine the incidence of UTI in the NICU population without predisposing UTI factors when fluconazole prophylaxis is administered to examine whether routine urinalysis would still be justified.
Rate of infants with a UTI who received 4 or more days of intravenous antibiotics decreased from 2005 to 2015.
Zanamivir is a neuraminidase inhibitor approved in the United States as an oral inhalation powder for acute, uncomplicated influenza in children ≥7 years of age and prophylaxis in children ≥5 years of age.
Identification of premature infants at low risk of early onset sepsis may help guide decisions for initiating and/or discontinuing empirical antibiotic treatments in the first days of life.
Researchers examine serious infection risk factors in patients with juvenile idiopathic arthritis receiving biologic therapy.
Study assessed the effects of weather trends on the occurrence and severity of acute hematogenous osteomyelitis in affected children.
New data shows a higher risk of respiratory syncytial virus hospitalization for preterm infants during the 2015-2016 season vs data from the previous season.
In recent years, a link between childhood Helicobacter pylori and gastric cancer in adulthood has elevated the need to detect and treat H pylori in asymptomatic children.
Maternal hypertension, intravascular thrombosis, and Gram-negative sepsis were independent risk factors for thrombocytopenia in multivariate analysis.
Addition of previously unconsidered genes from the PERSEVERE model can improve mortality risk stratification for children with septic shock.
Guidelines have been updated for infection prevention in pediatric ambulatory settings.
Vancomycin administered via continuous infusion was found to achieve the recommended VAN trough of 15-20mg/L faster and with less risk of adverse events compared to administration via intermittent infusion.
Many of the recommendations by sports organizations are more stringent than ordinary infection control practices for similar conditions.
The FDA has approved labeling changes for Genvoya to include new safety and efficacy data.
Hear from experts on when to prescribe short course antibiotic therapy in pediatric populations for a variety of common infections.
The has expanded the use of Rapivab to pediatric patients aged ≥2 years with acute uncomplicated influenza
Pediatric patients with group A streptococcal pharyngitis should not be treated with antibiotics if results of an RADT are negative.
An analysis of the financial burden associated with rotavirus infection revealed a lower cost burden for children receiving complete and incomplete vaccination relative to completely unvaccinated children.
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Strategies for Preventing Group B Streptococcus in Infants
- Safety of Clofazimine in Treating Children With Mycobacterium abscessus Infections
- Food Additive Linked to Growing Incidence of Clostridium difficile
- Prevalence of MRSA in ICU Patients After State-Mandated Surveillance
- CDC: Multistate Outbreak of E coli Being Investigated
- Universal Influenza Vaccine: A Game Changer in Prevention
- Guideline Update for Influenza Vaccine in Patients With Egg Allergy
- Update to Pulmonary Tuberculosis Screening Recommendations
- Meningococcal B Vaccine Elicits Bactericidal Responses Against Diverse Strains
- Alternative Therapeutics for Mild Infections May Help to Retain Antibiotic Efficacy
- Insulin Resistance in HCV May Be Reversed With DAAs
- SHEA Releases Contact Precaution Guidelines for Multidrug-Resistant Infections
- Cost-Effectiveness of New Adjuvanted Herpes Zoster Subunit Vaccine
- New Two-Dose Hepatitis B Vaccine for Adults Now Available
- Gastric Acid Inhibitors May Increase Late-Onset Sepsis Risk in Preterm Infants